Literature DB >> 15257681

Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis.

T L Sørensen1, R M Ransohoff, R M Strieter, F Sellebjerg.   

Abstract

The chemokine monocyte chemoattractant protein (MCP)-1/CCL2 and its receptor CCR2 have been strongly implicated in disease pathogenesis in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (MS), whereas data on the CCL2-CCR2 axis are scarce in MS. We studied the expression of CCR2 on leukocytes in blood and cerebrospinal fluid (CSF) from patients with monosymptomatic optic neuritis and MS, and the concentration of CCL2 in the CSF from these patients. Results were compared with the results in non-inflammatory neurological controls and were correlated with other parameters (magnetic resonance imaging and CSF data). Our findings suggest a limited role for CCL2/CCR2 in early active MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257681     DOI: 10.1111/j.1468-1331.2004.00796.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  28 in total

Review 1.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 2.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

3.  Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.

Authors:  Edgardo Laborde; Robert W Macsata; Fanying Meng; Brian T Peterson; Louise Robinson; Steve R Schow; Reyna J Simon; Hua Xu; Kunihisa Baba; Hideaki Inagaki; Yoshiro Ishiwata; Takahito Jomori; Yukiharu Matsumoto; Atsushi Miyachi; Takashi Nakamura; Masayuki Okamoto; Tracy M Handel; Claude C A Bernard
Journal:  J Med Chem       Date:  2011-02-22       Impact factor: 7.446

4.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

5.  Serine lipids of Porphyromonas gingivalis are human and mouse Toll-like receptor 2 ligands.

Authors:  Robert B Clark; Jorge L Cervantes; Mark W Maciejewski; Vahid Farrokhi; Reza Nemati; Xudong Yao; Emily Anstadt; Mai Fujiwara; Kyle T Wright; Caroline Riddle; Carson J La Vake; Juan C Salazar; Sydney Finegold; Frank C Nichols
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

Review 6.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

7.  Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis.

Authors:  Hideto Nakajima; Masakazu Sugino; Fumiharu Kimura; Toshiaki Hanafusa; Toshiyuki Ikemoto; Akira Shimizu
Journal:  Biomark Insights       Date:  2007-12-18

8.  Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.

Authors:  Masaki Kobayashi; Yuko Shimizu; Noriyuki Shibata; Shinichiro Uchiyama
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

9.  Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis.

Authors:  Adi Vaknin-Dembinsky; Gopal Murugaiyan; David A Hafler; Anne L Astier; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2008-04-10       Impact factor: 3.478

10.  Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide.

Authors:  Ray Chui; Katerina Dorovini-Zis
Journal:  J Neuroinflammation       Date:  2010-01-04       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.